Kymera Therapeutics, Inc. vs Johnson & Johnson
KYMR vs JNJ — side-by-side comparison from reported financials. KYMR leads 2, JNJ leads 6 of 8 comparable metrics.
Kymera Therapeutics, Inc.
KYMR · Healthcare
$112.40+2.84%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | KYMR | JNJ |
|---|---|---|
| Price | $112.40 | $261.79 |
| Market cap | $9.35B | $631B |
| Revenue (TTM) | $105M | $97.9B |
| Revenue growth | -5.8% | +5.6% |
| Net margin | -285.3% | 21.5% |
| Free cash flow | -$238M | $22.2B |
| Net cash (debt) | $766M | ($27.8B) |
| 1-year price return | +97.1% | +37.0% |
| P/E | — | 29.9 |
| P/E vs own history (cheap-side %) | — | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | -22% | 26% |
| Altman Z-score | 47.67 | — |
| CV checks passed | 4 of 9 | 10 of 9 |
| Employees | 273 | 140,800 |
Full résumé-style profiles: KYMR CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.